Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anshumaan Maharaj"'
Autor:
Anil K. Sood, Lee M. Ellis, Gabriel Lopez-Berestein, Scott Kopetz, Heather J. Dalton, Behrouz Zand, Vianey Gonzalez-Villasana, Trent A. Waugh, Kshipra M. Gharpure, Maria Pia Morelli, Archana S. Nagaraja, Cristian Rodriguez-Aguayo, Salma Azam, Anshumaan Maharaj, Rajat Bhattacharya, Takeshi Hisamatsu, Rajesha Rupaimoole, Justyna Filant, Seth Bellister, Sherry Y. Wu, Chad V. Pecot
Despite being among the most common oncogenes in human cancer, to date, there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS-mutated cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45069e66acfdb62f9a68c3ddef56c59
https://doi.org/10.1158/1535-7163.c.6536494
https://doi.org/10.1158/1535-7163.c.6536494
Autor:
Anil K. Sood, Lee M. Ellis, Gabriel Lopez-Berestein, Scott Kopetz, Heather J. Dalton, Behrouz Zand, Vianey Gonzalez-Villasana, Trent A. Waugh, Kshipra M. Gharpure, Maria Pia Morelli, Archana S. Nagaraja, Cristian Rodriguez-Aguayo, Salma Azam, Anshumaan Maharaj, Rajat Bhattacharya, Takeshi Hisamatsu, Rajesha Rupaimoole, Justyna Filant, Seth Bellister, Sherry Y. Wu, Chad V. Pecot
Supplementary figure 1 provides a schematic of DOPC:siRNA nanoliposomal preparation, and Supplementary figure 2 shows tumor volumetric measurements of the A549 orthotopic lung cancer therapeutic experiment described in the main figure 2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80d907673a1dc060bb20e19e28da20da
https://doi.org/10.1158/1535-7163.22500544
https://doi.org/10.1158/1535-7163.22500544
Autor:
Salma H. Azam, Scott Kopetz, Sherry Y. Wu, Heather J. Dalton, Archana S. Nagaraja, Rajat Bhattacharya, Rajesha Rupaimoole, Anil K. Sood, Anshumaan Maharaj, Chad V. Pecot, Trent A. Waugh, Cristian Rodriguez-Aguayo, Kshipra M. Gharpure, Vianey Gonzalez-Villasana, Takeshi Hisamatsu, Lee M. Ellis, Gabriel Lopez-Berestein, Justyna Filant, Seth Bellister, Maria Pia Morelli, Behrouz Zand
Despite being among the most common oncogenes in human cancer, to date, there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS-mutated cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f02b7c9f6c7a41a5b62b26f1daf9771
https://europepmc.org/articles/PMC4416486/
https://europepmc.org/articles/PMC4416486/
Autor:
Seth Bellister, Lee M. Ellis, Gabriel Lopez-Berestein, Anshumaan Maharaj, Anil K. Sood, Cristian Rodriguez-Aguayo, Vianey Gonzalez-Villasana, Chad V. Pecot, Rajat Bhattacharya, Rajesha Rupaimoole, Sherry Y. Wu
Publikováno v:
Molecular Cancer Research. 12:B47-B47
Introduction: Despite being amongst the most common oncogenes in human cancer, to date there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs using biocompatible nanoparticles
Autor:
Cristian Rodriguez-Aguayo, Vianey Gonzalez-Villasana, Thiru Arumugam, Anshumaan Maharaj, Gabriel Lopez, Behrouz Zand, Anil K. Sood, Chad V. Pecot, Sherry Y. Wu, Rajesha Rupaimoole
Publikováno v:
Cancer Research. 73:938-938
Introduction: Despite being one of the first known oncogenes in human cancer, to date there are no effective therapeutic options for inhibiting KRAS. We investigated whether systemically delivered KRAS siRNA using biocompatible nanoparticles has ther